Cobicistat Versus Ritonavir as a Pharmacoenhancer of Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naive HIV Type 1–Infected Patients: Week 48 Results-Reference-Cited by-同舟云学术

Cobicistat Versus Ritonavir as a Pharmacoenhancer of Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naive HIV Type 1–Infected Patients: Week 48 Results

Published:2013-03-26 Issue:1 Volume:208 Page:32-39
ISSN:1537-6613
Container-title:The Journal of Infectious Diseases
language:en
Short-container-title:

Author:

Gallant Joel E.,Koenig Ellen,Andrade-Villanueva Jaime,Chetchotisakd Ploenchan,DeJesus Edwin,Antunes Francisco,Arastéh Keikawus,Moyle Graeme,Rizzardini Giuliano,Fehr Jan,Liu Yapei,Zhong Lijie,Callebaut Christian,Szwarcberg Javier,Rhee Martin S.,Cheng Andrew K.

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Immunology and Allergy

Link

http://academic.oup.com/jid/article-pdf/208/1/32/16867038/jit122.pdf

Reference28 articles.

1. Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents;Hsu;Clin Pharmacokinet,1998

2. Cobicistat (GS-9350): a potent and selective inhibitor of human CYP3A as a novel pharmacoenhancer;Xu;ACS Med Chem Lett,2010

3. Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infection;Elion;AIDS,2011

4. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel;Thompson;JAMA,2012

Cited by 105 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Outcome of Darunavir–Cobicistat-Based Regimens in HIV-Infected People Who Have Experienced Virological Failure;Drug Design, Development and Therapy;2024-04

2. Discontinuation of tenofovir disoproxil fumarate from initial ART regimens because of renal adverse events: An analysis of data from four multi-country clinical trials;PLOS Global Public Health;2024-01-04

3. Unveiling drug induced nephrotoxicity using novel biomarkers and cutting-edge preventive strategies;Chemico-Biological Interactions;2024-01

4. Synthesis and characterization of two known and one new impurities of dolutegravir: In silico evaluation of certain intermediates against SARS CoV-2 O-ribose methyltransferase (OMTase);Journal of Molecular Structure;2023-01

5. A clinical review of HIV integrase strand transfer inhibitors (INSTIs) for the prevention and treatment of HIV-1 infection;Retrovirology;2022-10-22